Rezolute Highlights Ersodetug Program at ENDO, But No Thesis-Changing Data

What happened

Rezolute presented analyses from natural history studies in congenital hyperinsulinism and previously reported Phase 3 sunRIZE results at the ENDO meeting. The sunRIZE data confirmed the failure on primary and key secondary endpoints, underscoring the regulatory hurdle in congenital HI. The company also showcased a case series from its Expanded Access Program in tumor HI, which had previously supported FDA's acceptance of a streamlined Phase 3 upLIFT design. While the presentations reinforce the unmet need and mechanistic rationale for ersodetug, they do not introduce any new clinical data that alters the binary outlook. Investors remain focused on upcoming FDA feedback on congenital HI salvage and the 2H26 upLIFT readout as the true value drivers.

Implication

The ENDO presentations are backward-looking, reiterating known data. The investment thesis remains unchanged: Rezolute's value hinges on resolving the congenital HI salvage path with FDA and delivering positive upLIFT results in tumor HI. Without new data shifting the risk-reward, we maintain a WAIT stance. The stock could see modest movement based on conference sentiment, but we view that as noise. Position sizing should remain small until either the FDA meeting in Q1 2026 (past) or the 2H26 readout provides clarity. The current cash runway extends to mid-2027, offering a buffer but not eliminating binary risk.

Thesis delta

The ENDO data dump confirms known outcomes from the failed sunRIZE trial and positive but limited EAP experience in tumor HI. No new data points were presented that would change the probability of success for either program. Therefore, the thesis remains unchanged: Rezolute is a high-risk, binary story dependent on upcoming regulatory and clinical milestones.